Voluntary licensing for medicines faces uncertain future; 3 drug pricing issues to watch in 2023

Voluntary licensing holds some promise for improving drug access in low- and middle-income countries, but hurdles remain. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: 'Stuck in a rut': As debate flares over access to medicines, the future of voluntary licensing is up in the air By Ed Silverman Mike Reddy for STAT Voluntary licensing holds some promise for improving drug access in low- and middle-income countries, but hurdles remain. Read More STAT+: 3 drug pricing issues to watch in 2023 By Rachel Cohrs Christine Kao/STAT The legislative saga on drug pricing is mostly over for now, but drug pricing policy will still offer plenty of controversy in 2023. Read More STAT+: Biogen shakes up R&D chief role, makes Singhal permanent replacement By Allison DeAngelis Ruby Wallau for STAT Priya Singhal, who has served as interim R&D chief since November 2021, will serve as the new head of development at Biogen. Read More Sponsored Insight by STAT+ You're invited to STAT's JPM Recap On Jan. 13, get a full rundown of the deals, data, and scuttlebutt from the STAT reporters who attended the conference, and come away with insights you won't get anywhere else. Sign up here. STAT+: Pharma's ambitious antibiotic venture fund makes another investment By Ed Silverman Melissa Brower/Centers for Disease Control and Prevention via AP The fund invested $7.5 million in BioVersys, which is developing an antibiotic to combat a type of bacteria that affects hospitalized patients. Read More Opinion: Health record interoperability needs to include dental health records By Kiltesh Patel OLIVIER DOULIERY/AFP via Getty Images New rules to make health records more easily available and interoperable should be expanded to include dental health records. Read More Listen: #JPM23, the future of Alzheimer's, & rising Covid variants By Damian Garde and Meg Tirrell and Adam Feuerstein We delve into a sweeping congressional investigation into the FDA's approval of the last treatment for Alzheimer's. Read More Thursday, January 5, 2023       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser